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Supplementary Figure 1. Endocannabinoid- and phytocannabinoid-sensitivity of brain 
tumor cells. (A) Mouse transgenic glioma with different combinations of genetic driver 
mutations were established: Transgenic glioma harbored Tp53 point-mutations or ablation of 
Tp53, Cdkn2a, Pten or Nf1 (indicated by “-”), overexpression of PDGFRB (P) or mutant EGFR 
(vIII); cytotoxicity (fold-change) of transgenic glioma cells induced by neural precursor cell 
(NPC) released factors (NPC-conditioned medium containing endocannabinoids) was 
quantified; wild-type (WT) NPCs were used as controls. (B) Human, primary, stem-like 
glioblastoma cells (hGSC; named NCH684) were exposed to vehicle (0.01% DMSO) or 
stimulated with a range of non-psychotropic phytocannabinoids: Cannabigerol (CBG), 
Cannabidivarin (CBDV), Cannabichromene (CBC), Tetrahydrocannabivarinic Acid (THCVA), 
Cannabidiolic Acid (CBDA), Cannabigevarin (CBGV), Cannabidivarinic Acid (CBDVA) 
Cannabigerolic Acid (CBGA) or Cannabidiol (CBD) and cytotoxicity was quantified. (C) Human, 
primary, stem-like glioblastoma cells (hGSC; named NCH644) were exposed to vehicle (0.01% 
DMSO) or stimulated with a range of non-psychotropic phytocannabinoids (as in B) and 
cytotoxicity was quantified. Dots (in A - C) represent data from independent experiments; 
statistical significance in (A and D) was investigated by One-Way ANOVA with Bonferroni´s 









Supplementary Figure 2. Pharmacogenomics reveal a central role for NFΚB and 
selenoproteins in CBD-induced hGSC cell-death. (A) Knockouts (induced with a genome-
wide CRISPR knockout-library in CBD-sensitive, CAS9-expressing Tp53R172H, PDGFB  
tmBTCs) that were more than 10,000-fold enriched (as compared to vehicle-treated controls) 
in cells surviving CBD-application were identified (see supplemental table-1) and investigated 
by an algorithm for biological network reconstruction through text-mining (ChiliBot); 
permutations of pairwise searches suggested a role for three genes (Emap-II, Hnrnp and Ikbkb, 
identified by the pharmacogenomics-screen) in canonical (TNFα mediated) NFΚB -signaling; 
integration of TNFα and the NFΚB -subunit RelA together with the three identified genes in a 
gene-list query revealed the network-connections  shown in (A). (B)  The CRISPR-screen 
identified selenocysteine insertion sequence-binding protein 2-like (Secisbp2l) as a genetic 
ablation converting CBD-sensitive into CBD-insensitive tmBTCs (see supplemental table-2); 
Secisbp2l is part of the selenoprotein synthesis pathway in mice (participates in the 
selenocysteine-insertion pathway, as determined by interrogation of the STRING database). 
(C) The preponderant selenocysteine binding protein in humans is encoded by SECISBP2, but 
ablation of this gene (by CRIPR/Cas9-mediated knockout) is detrimental for cancer cell-
viability, while loss of SECISBP2L is non-abrasive (numerical values reaching -0.5 or lower 
show cells do not tolerate a knockout, while positive values indicate tolerance, as observed 
DepMap database for CRISPR/Cas9 knockout studies); altogether, this can explain why 
SECISBP2L (but not SECISBP2) was found in our screen: SECISBP2L-knockouts are 
tolerable, but are predicted to have consequences for the synthesis of selenoproteins. (D) Q-
PCR confirmed CBD-mediated downregulation of PKCζ (as compared to other genes of the 
NFΚB -pathway). (E) Role of PKCζ in the canonical NFΚB pathway: Inflammatory cytokines 
(TNFα) initiate nuclear accumulation of RELA and simultaneous RELA-phosphorylation (on 
Ser311) by PKCζ, which is required for transactivation. Dots in (D) represent data from 
independent experiments; statistical significance (D) was investigated by One-Way-ANOVA 




Supplementary Figure 3. Cell-death in CBD-treated hGSC is executed by apoptosis or 
non-apoptotic pathways. (A) CBD-induced cell-death in human stem-like glioblastoma cells 
(hGSC) named GBM10, GBM20 or GBM29 was quantified in a cytotoxicity assay over a 
concentration range; cytotoxicity is shown as fold-change versus vehicle control (0.01% 
DMSO); robust hGSC-death (more than 2fold change) was obtained with ≥ 8 µM CBD. (B) 
Effects of short CBD-pulses were investigated by counting hGSC under control conditions 
(grey bars) or after CBD application (10 µM CBD for 6 h; CBD-sensitive cells: red-bars; CBD-
insensitive cells: blue-bars), 48 h after stimulation (control or CBD) viable cells were quantified; 
note that pulsed CBD application strongly attenuated the number of viable CBD-sensitive 
hGSC (but spared CBD-insensitive cells). (C) Biopsies from high-grade astrocytomas were 
maintained for very short time in vitro (tumors 139, 142 and 143 for three passages, tumor 140 
for 4 passages and tumors 138 or 141 for 6 respectively 7 passages), CBD (or vehicle; 
controls) was applied as described and cytotoxicity was quantified (n=3 measurements); 
statistically significant induction of GBM-death by a factor of 2 or more (corresponding to a 
strong reduction in overall GBM cell viability, as shown in B) is indicated (#). (D) To determine 
if CBD-induced hGSC-death is executed via apoptosis we co-applied the pan-Caspase 
inhibitor Q-VD-Oph together with CBD and determined cytotoxicity as compared to negative 
(vehicle or Q-VD-Oph alone) and positive controls (CBD alone). CBD-mediated cell-death was 
corroborated in all CBD-sensitive hGSC; note that Q-VD-Oph efficiently blocked cell-death in 
a subset of p53 wild-type hGSC. (E) CBD-sensitive hGSC were exposed to CBD or vehicle 
(control; Ctrl), stained with an antibody specific for cleaved Poly-ADP-ribose-Polymerase 
(PARP) and inspected by flow cytometry; fractions of cells immunopositive for cleaved PARP 
were quantified, controls were arbitrarily defined as “1” and CBD-stimulated samples are 
shown as fold change relative to controls. (F) CBD-sensitive hGSC were stimulated with CBD 
or vehicle (control), stained with an antibody for p62 / sequestosome-1 (SQSTM) and fractions 
of cells immunopositive were quantified FACS, controls were arbitrarily defined as “1” and 
CBD-stimulated samples are shown as fold change relative to controls. (G) CBD-sensitive 
hGSC were incubated with vehicle (control), the ER-stress inducer Eeyarestatin-I (Eey-I; at a 
non-toxic concentration), CBD and combined CBD+Eey-I; note that Eey-I and CBD 
cooperatively induce hGSC cell-death (as determined by quantification of cytotoxicity). 
Statistical significance was investigated by One-Way ANOVA with Bonferroni´s pair-wise 





Supplementary Figure 4. CBD-induced shifts in hGSC-metabolic cues are required for 
cell-death execution. (A) Viability of CBD-sensitive human or mouse GBM cells was reduced 
by PKCζ-inhibition (in a dose-dependent manner). (B) Expression levels of key molecules for 
glucose uptake (SLC2A1, SLC2A3, HK1 and HK2) were determined by quantitative PCR under 
control conditions (arbitrarily set as “1”, shown as dotted line) and after CBD-stimulation (fold-
change from controls). (C) Mitochondrial-superoxide (SOX); (D) mitochondrial-mass, and -
membrane-potential (MMP) were determined in a range of CBD-sensitive and –insensitive 
hGSC with or without CBD-application. The CBD-insensitive hGSC did not undergo any CBD-
induced changes in mitochondrial physiology while CBD-sensitive tumor cells showed a 
profound increase in mitochondrial-SOX, -mass and –MMP (as compared to vehicle controls). 
(E) The glutamate dehydrogenase inhibitor EGCG largely abrogated CBD-induced hGSC-
death. (F) Proposed model for glutamate dehydrogenase (GDH) and RELA in a feed-forward 
cycle for CBD-induced hGSC-cytotoxicity: CBD-attenuated glucose-uptake (A) necessitates 
metabolic adaption (B and C) through GDH (D), which is well established to promote nuclear 
localization of RELA under low glucose conditions (thereby spurring on nuclear accumulation 
of RELA lacking phosphorylation on Ser311). Statistical significance was investigated by One-










Supplementary Figure 5. CBD-sensitivity of hGSC is not predicted by established 
markers for GBM-subsets or phytovanilloid signaling. (A) Human primary hGSC were 
grouped according to GBM-subtypes (color-coded as proneural, classical or mesenchymal ; 
“mixed” comprises GBM previously designated as “neural”; N.D., not determined as exhibited 
in Supplemental Table-1), treated as described in Figure-1a (maintained under control 
conditions or treated with CBD); after 48 h cytotoxicity was quantified: Controls (bars with white 
pattern) were arbitrarily set as “1” and fold-change of CBD-induced cytotoxicity (as compared 
to controls) is indicated; note that CBD-sensitivity has no stringent relation with GBM-subtypes. 
(B) CBD-induced cell-death was previously related to activation or inhibition of different 
receptors or the transcription factor ID1; expression levels for these molecules were 
determined by qPCR (see list of symbols for each gene; log2 expression levels are presented; 
ND = not detected) and related to the cytotoxicity observed after CBD-application (symbols for 
CBD-sensitive hGSC in red, CBD-insensitive hGSC in blue); note that there is no correlation 
of expression-levels with CBD-sensitivity. (C) Copy number alterations (as determined by 
SNP-arrays) for genes listed in (B) or for known driver-mutations of human GBM (D) were 
inspected in CBD-sensitive (red) or CBD-insensitive hGSC (blue); note that there are no copy-
number alterations that are specifically enriched in CBD-sensitive / insensitive hGSC; 








Supplementary Figure 6. Low ROS-levels are restricted to CBD-sensitive hGSC, while 
genetic alterations of NFΚB-pathway components are shallow and non-discriminatory. 
(A) A set of 22 genes representing the core of the canonical NF-ΚB pathway were investigated 
for copy-number alterations present in hGSC cells used in this study (data for 21 genes are 
shown, the gene CYLD was never altered and is therefore absent from the list), data were 
visualized by OncoPrint, symbols (Genetic Alteration) indicate presence / absence of 
mutations; note that there were no genetic alterations specifically enriched in CBD-sensitive / 
insensitive hGSC (interrogation of the TCGA-database for GBM confirmed that point-mutations 
for these genes were extremely rare: Missense mutations of unknown significance occurred 
only in a total of 10 samples, out of 257 samples; no sample contained more than one 
mutation). (B) Flow cytometry was used to determine soluble equivalent of fluorescein (MESF) 
for H2DCFDA (providing a quantitative assessment for reactive oxygen species; ROS) in a 





Supplementary Figure 7. CBD-mediated therapeutic effects in immunocompetent 
models and calibration for flow cytometry. (A) CBD-mediated therapeutic effects were 
tested in two orthotopic, transgenic models corresponding to tmBTC characterized in vitro as 
CBD-sensitive or -insensitive; in a first step we induced GBM in transgenic mouse lines 
(cdkn2a-knockout mice or animals containing cre-inducible alleles for the Tp53 gain of function 
mutation R172H) by infusion (into the subventricular zone) of a vector inducing the expression 
of  PDGFB and cre-recombinase; subsequently, randomly selected mice were inspected for 
GBM growth; when tumor-take was confirmed pharmacological treatment (CBD or vehicle) 
was performed and overall survival (until a pre-defined humane endpoint) was monitored 
(summarized in a schematic); note that CBD-treatment (red-lines) of established tumors 
prolonged survival (as compared to controls; blue lines) specifically in gliomas that were 
identified as CBD-sensitive in vitro (p53R172H, PDGFB). (B) Bead calibration used for FACS-
instrument settings to determine equivalents of soluble fluorescein (for 2',7'-
dichlorodihydrofluorescein diacetate, H2DCFDA, measurement). (C) Cultivated hGSC cells 
were investigated for H2DCFDA-generated fluorescence by flow cytometry: The analysis was 
restricted to single, viable cells with sound fluorescence signals (as compared to negative 
controls; FMO) for oxidized H2DCFDA. (D) hGSC were excised from mouse brains, separated 
into single-cell suspensions, immunostained for human MHC (HLA, visualized with Alexa-647) 
and incubated with H2DCFDA, cells were investigated for fluorescent (oxidized) H2DCFDA 
and for Alexa-647 (immunofluorescence) by flow cytometry: The analysis was restricted to 
single, viable cells with sound fluorescence signals (as compared to negative controls; FMO) 
for Alexa-647 and with reliable detection for H2DCFDA (as compared to negative controls; 
FMO).  
  
MATERIALS AND METHODS 
Cell culture 
Biopsies from human primary and recurrent hGSC were obtained from planned resections 
(approval was obtained from the ethics committee of Charité university clinics, license numbers 
EA112/2001, EA3/023/06 and EA2/101/08 and from the university clinics Kiel, license number 
D-408-14 and D-562-15; for primary cell cultures obtained from high-grade astrocytomas 
referenced in supplemental table-3) and cultured under neurosphere conditions at 37°C in a 
humidified atmosphere of 5% CO2; in cell-culture media previously established to maintain 
stem-like properties (see Supplemental table-1 for specification and references): DMEM/F12 
containing B27 cell-culture supplement and EGF, FGF (both at 10 ng/ml; GBM10, GBM13, 
GBM14, GBM20, GBM29, BT112, BT172, BT423) or in NeuroCult basal medium containing 
NeuroCult proliferation supplement and EGF, FGF (both at 10 ng/ml; for Line2, Line6, Line7, 
Line8, Line9, Line10, Line11, NCH441, NCH421K, NCH588J, NCH592B, NCH644, 
NCH684). Cells were passaged 3 times per week using a seeding density of 0,3-0,5x 106 
cells/10ml. Tumorigenic capacity of hGSC cells was determined after orthotopic implantation. 
Mycoplasma were regularly tested and affected cells were discarded. Drugs were applied at 
concentrations indicated in the text and were diluted into DMSO (final concentration of DMSO 
was 0.01%); consequently we used 0.01% DMSO as vehicle solution. Biopsies from high-grade 
astrocytomas were freed from blood vessels, connective tissue and meninges as far as possible, 
dissociated mechanically in Dulbecco’s modified Eagle’s medium (DMEM; Thermo Fisher 
Scientific, Waltham, MA, USA) plus 0.05% DNase plus 0.03% trypsin, cultured in DMEM 
supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific), 1% penicillin–
streptomycin (10,000 U/ml; Thermo Fisher Scientific), and 2 mM additional L-glutamine 
(Thermo Fisher Scientific), and subcultivated every 2–4 weeks by trypsinization. Purity of the 
high-grade astrocytoma cells was ascertained by immunostaining with cell type specific 
markers, and by the absence of contamination with mycoplasms. Tumors were diagnosed and 
classified according to WHO criteria by a pathologist. 
ARRIVE guidelines were followed for all animal experiments. Permissions for animal 
experimentation were obtained from the local authorities (Regierung von Oberbayern) and all 
precuders were performed in accordance with local rules and regulations. Brains from C57/BL6 
wild-type and transgenic mice were harvested at postnatal day 30 (P30), the subventricular zone 
(SVZ) was dissected, dissociated (using trypsin and collagenase), washed with DMEM-10% 
FCS and transferred into NPC culture medium (DMEM/F12 containing B27 supplement, EGF 
and FGF both at 10 ng/ml. Once neurosphere-formation was observed spheroids were triturated 
and expanded (until sphere size reached 200 – 250 µm). Neural stem and precursor cell capacity 
was verified by self-renewal capacity and by established multi-lineage differentiation 
paradigms (clonal plating, growth factor withdrawal and adherent cultivation on ornithine-
laminin coated surface followed by immunofluorescence staining for neuronal and glial 
markers; see antibody-list) confirming that cultivated cells were bona fide NPCs. NPCs from 
transgenic mice were stably transfected or virally transduced with vectors for the expression of 
cre-recombinase, different proto-oncogenes (see vector-list) or both. Genetic manipulations 
were controlled by the expression of vector derived reporters (GFP or RFP), by PCR and/or 
Western-blotting.  
Genetic characterization of hGSC 
Genomic DNA (gDNA) and total RNA were isolated in parallel from samples (with sample-
IDs indicated in supplemental table-1); DNA libraries were prepared using the TruSeq Custom 
Amplicon Low Input kit (Illumina, Inc.). Using the Illumina Design Studio (with hg19 as a 
refernce; targeted amplicon size of 250 bp) we generated an amplicon-based enrichment panel 
(TruSeq Custom Amplicon Low Input). With this approach we enriched for genes often 
exhibiting point-mutation in hGSC(27) (see table “amplicons”, below). Sequencing was 
performed on the Illumina MiSeq sequencing system (Illumina Inc.; 2 x 250 bp paired-end). 
The resulting reads were quality controlled and mapped against the human reference genome 
(hg19). For all samples, sequence variations of the amplified regions of interest in comparison 
to the human reference sequence were identified and filtered based on reliability. Additionally, 
genome-wide copy number variation (CNV) profiles were analyzed from gDNA using the 
CytoScan assay in combination with a one-color based labeling and hybridization protocol. 
Signals on the CytoScan HD microarrays were detected using the Affymetrix GeneChip 3000 
Scanner. Raw data were quality controlled and analyzed for copy number variations using the 
Affymet-rix ChAS software.  
Table: Amplicons analyzed in hGSC 
Gene Symbol  Official Gene Name  Gene ID  Chromosome   
ATRX1  Apicoplast-associated thioredoxin family 
protein  
546  X   
EGFR  Epidermal growth factor receptor  1956  7   
IDH1  isocitrate dehydrogenase (NADP(+)) 1  3417  2   
NF1  neurofibromin 1  4763  17   
PDGFRA  platelet derived growth factor receptor 
alpha  
5156  4   
PIK3CA  phosphatidylinositol-4,5-bisphosphate 3-
kinase catalytic subunit alpha  
5290  3   
PIK3CG  phosphatidylinositol-4,5-bisphosphate 3-
kinase catalytic subunit gamma  
5294  7   
PIK3R1  phosphoinositide-3-kinase regulatory 
subunit 1  
5295  5   
PTEN  phosphatase and tensin homolog  5728  10   
RB1  RB transcriptional corepressor 1  5925  13  
TP53  tumor protein p53  7157  17  
 
Transgenic mouse models 
Transgenic mouse glioma models were obtained from mouse strains with germ-line or 
conditional knockouts for tumor suppressors deleted in hGSC(27), which were (partly) 
combined with conditional models for the deletion of Rela (p65)(48). All transgenic mouse 
strains were bred and raised at the animal facilities of the University Clinics Munich and the 
clinics of the Technical University Munich according to German law on animal welfare and 
approved by the “Regierung von Oberbayern” in Munich, Germany. 
 
Transgenic mouse strains  
Strain 
 
Source Identifier Reference  
Ai9(RCL-tdT) JaxLab 007909 Nat Neurosci. 2010, 13 (1): 
133-40 
 
Cdkn2A-/- NCI Frederick Ink4A/Arf null 
(B6) 
Cell. 1996, 5;85(1): 27-37  
Tp53LSL.R172H JaxLab 034620 Cell. 2004, 119(6): 847- 
60 
 
Tp53KO JaxLab 002101 Curr Biol. 1994, 4(1):1-7  
Tp53LoxP JaxLab 008462 Genes Dev. 2000,  14(8): 
994-1004 
 
Relatm1Rsch  MGI ID:  
3713697 
J Clin Invest. 2007; 
117(6):1490-501 
 
PTEN flox JaxLab 006440 Genesis. 2002, 32(2): 
148-9 
 
mT/mG, dual RFP / 
GFP reporter 
JaxLab 007676 Genesis. 2007, 45 (9): 
593-605. 
 




The genes encoding Tp53 and Nf1 are located on the same chromosome and linked Tp53 and 
Nf1double-transgenic mice were obtained (through crossing over events in meiosis) after 
several generations of breeding. Human GSC cells were orthotopically implanted into 
B6.129S6-Rag2tm1Fwa N12 (immunodeficient Rag2-KO) mice (purchased from Taconic). 
Plasmid transfection into mammalian cells 
Cells were seeded into serum- and antibiotics-free medium, 3µg of plasmid was mixed with 
OptiMem and Plus-reagent, then lipofectamine was added (all from Thermo Fisher Scientific), 
the mixture was incubated and subsequently applied to the plated cells. After 24 h cells were 
plated into selection medium (for stable transfection); selective agents were omitted during 
experiments.                                                                                                         
 
ORF-Sources for gene-expression constructs 
ORF 
 
Species Provider Identifier Reference  
TP53 Human Addgene #69003 Nucleic Acids Res. 2014,  
42(12): 7666-80 
 
TP53 Mouse  Addgene #12139 J Cell Physiol. 1998, 177(2): 
364-76 
 
TP53V133A Human Addgene #16435 Science. 1990, 249(4971):912-
5 
 
TP53R175H Mouse Addgene #14854 Cell. 2004, 119(6):847-60  
TP53R175H Human Addgene #16436 Science. 1990, 249(4971):912-
5 
 
TP53R248W Human Addgene #16437 Science. 1990, 249(4971):912-
5 
 
TP53R249S Human Addgene #16438 Science. 1990, 249(4971):912-
5 
 
TP53R273H Human Addgene #16439 Science. 1990, 249(4971):912-
5 
 
EGFR  Human  Addgene #44185 Biochemistry. 2008, 47(39): 
10314-23 
 
EGFRvIII Human Addgene #20737 Neuro Oncol. 2009, 11(1):9-21  
PDGFB Human Malatesta, 
P. 





ORFs for the expression of wild-type or mutant forms of RelA (mouse) were generated as 










































Takara #631080   
 
Pantropic virus production and transduction 
Lentiviruses were generated using the Mission third generation lentiviral packaging system 
(Merck). HEK293T were plated co-transfected with packaging mix and transfer vector 
containing the gene of interest, 24 h later cells obtained fresh medium; lentiviral particles 
were harvested on day 2 and 3 post-transfection, filtered, aliquoted and stored at -80°C until 
use. For in vivo applications VSV-G coated virus-particles were sedimented (concentrated) by 
ultra-centrifugation (200,000 g) and virus titers of 5x 109 cfu (or higher) were obtained 
CRISPR/Cas9 screen 
Mouse glioma cells were infected with the genome-wide gRNA lentiviral library(49) (Addgene 
#50947) at an MOI of 0.3. Three days after infection, 3.5 × 106 BFP-positive cells were sorted 
and cultured for an additional 4 days. Then, transduced cells were split into two fractions of 
equal cell-number and treated with CBD or with vehicle (0.01% DMSO; controls) for 16 h. 
Then media were exchanged (to fresh medium without DMSO or CBD) and surviving cells 
were expanded for 6 days (separately in each experimental group).  Genomic DNA was 
extracted and used for PCR templates. gRNA was amplified (Hot start PCR) using 15 ng of the 
whole-genome lentiviral plasmid library per reaction. The PCR products were purified with 
Agencourt AMPure XP beads in a PCR-product-to-bead ratio of 1:0.7. The purified libraries 
were quantified and sequenced on Illumina HiSeq2500 by 50-bp single-end sequencing (for the 
entire libraries gRNA sequences were extracted by removing constant regions from each read 
and these were used to count quantify and assign the number of reads of each gRNA in the 
library using Encore software(50). 
Transcriptomics 
Total RNA was isolated from cell-pellets using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions including on-column DNase digestion; RNA concentration was 
determined (NanoDrop ND-1000 spectral photometer; Peqlab). High-quality total RNA 
samples (A260/A280 ratio ≥ 1.9; A260/A230 ratio ≥ 2.0) were used for subsequent steps of 
RNA quality control (2100 Bioanalyzer with RNA 6000 Nano and Pico LabChip Kits; Agilent 
Technologies) and samples with RIN values ≥9 were used for library preparation (TruSeq 
Stranded mRNA HT technology). Then, all samples were again quality controlled (DNA 1000 
LabChip kits on the 2100 Bioanalyzer; Agilent Technologies). These samples showed a clear 
and pure band at approximately 260 nt, DNA concentration was determined and the sequencing 
library was quantified (Qubit ds DNA HS Assay Kit ; Invitrogen). Sequencing of the library 
was performed at a final concentration of 1.8 pM and with a 1% PhiX v3 control library spike-
in (Illumina) on the NextSeq500 sequencing system (Illumina). For cluster generation and 
sequencing of all samples, a high output single-end 75 cycles (1x75Bp SE) run was performed 
(NextSeq500). Sequencing was operated under the control of the NextSeq Control Software 
(NCS).  
Quantitative PCR 
RNA extraction and quality controls were performed as described above (transcriptomics). The 
High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific) was used for 
reverse transcription of total RNA into single stranded cDNA with the aid of random hexamer 
primers according to the manufacturer’s instructions. The cDNA samples were analyzed in 
triplicates; TaqMan Gene Expression Master Mix (Thermo Fisher Scientific) and the TaqMan 
assays indicated in table “PCR probes” were used for real-time PCR amplification. The 




Gene symbol TaqMan assay ID         Gene symbol TaqMan assay ID 
Ikbkg  Mm00494927_m1  Prkcz  Mm00776345_g1  
Nfkbib Mm00456853_m1  Prkcq  Mm00435802_mH  
Nfkbia Mm00477800_g1  Prkcd  Mm00440884_g1  
Ikk1  Mm00432529_m1  Prkcb  Mm00435749_m1  
RelA  Mm00501346_m1  Gapdh  Mm99999915_g1  
Nfkb2 Mm00479807_m1  ActB  Mm01205647_g1  
Nfkb1  Mm00476379_m1  IKBKG  Mm00494927_m1  
TRPA1  Hs00175798_m1  TRPV4  Hs01099348_m1  
TRPV1  Hs00218912_m1  TRPM8  Hs01066596_m1  
CNR2  Hs00361490_m1  ACTB  Hs01060665_g1  
PPARG  Hs01115513_m1  SLC2A1 Hs00892681_m1 
GAPDH  Hs02758991_g1  SLC2A3 Hs00359840_m1 
ID1  Hs00357821_g1  HK1 Hs00175976_m1 
GPR55  Hs00995276_m1  HK2 Hs00606086_m1 
TRPV2  Hs00901648_m1  TRPV3  Hs00376854_m1  
In vitro cytotoxicity assay 
Cytotoxicity was detected using the CytoTox-Fluor™ cytotoxicity assay from Promega. In 96 
well-plates, 3 x103 in 50µl (5 replicates per condition) were treated for 24 hours with 50µl of 
vehicle/drug in NPC medium without phenol red. 40µl of cells and diluted bis-AAF-R110 
substrate (1:1 ratio) incubated for 2 hours before measuring fluorescence intensity in a 
InfiniteF200 fluorescence plate reader (Tecan; 485nm Ex / 520nm Em); blanks were subtracted 
from all wells and the fluorescence read-out for untreated cells (vehicle control) was normalized 
to 1. Read-outs from treated cells were normalized to those of untreated cells and fold change 
of relative cytotoxicity calculated for each well. Outliers were detected and omitted, if any, 
using the Grubbs test. Graphs were generated using the GraphPad Prism software version 5.01. 
In vitro viability and proliferation assays 
The CellTiter Non-radioactive Cell Proliferation Assay (Promega) was used according to 
manufacturer´s instructions. Cells were seeded and treated as in the cytotoxicity assay. After 48 
hours of incubation at 37°C in a humidified atmosphere, each well incubated with 15µl of dye 
solution for 4 h at 37°C; 100µl of solubilization/stop solution was added to each well and 
incubated 1 hour at 37°C. The absorbance was then recorded using an absorbance plate reader 
set at 570nm (SoftmaxPro software). Blanks were subtracted from all wells and fold change to 
vehicle control was calculated. The CellTiter 96 AQueous Non-Radioactive Cell Proliferation 
Assay (Promega) was used according to manufacturer´s instructions. Cells were seeded and 
treated as in the MTT assay. After 72 h at 37°C in a humidified atmosphere, each well incubated 
with 20µl of MTS/PMS solution for 4 h at 37°C. To stop the reaction, 25µl of 10% SDS solution 
was added to each well and incubated 1 hour at 37°C. The absorbance was then recorded using 
an absorbance plate reader set at 490nm using the SoftmaxPro software. Blank was subtracted 
from all wells and fold change to vehicle control was calculated. 
Transcription factor binding array 
Transcription factor binding to cognate gene-promoter sequences was quantified with the ER 
Stress (UPR) TF Activation Profiling Plate array (Signosis; according to instructions), 
simultaneously indicating the DNA-binding activity of XBP-1, ATF4, ATF6, 
GADD153/CHOP, CBF/NFY, SREBP1, YY1, ERR, ATF3, AP-1, FOXO1, IRF, p53, NFΚB 
and NRF2/ARE; hGSC cells were inspected over a time-course after vehicle-treatment (control) 
or after stimulation with 10 µM CBD; reproducible data were obtained after 20 h of treatment 
/ control and fold-changes in DNA-binding of all TFs was calculated. 
Reporter-gene assay 
Patient-derived Glioblastoma cells were transfected with a reporter-construct encoding for the 
ProteoTuner™ Shield System N (Signosis; using lipofectamine, see above). Here, a 
destabilized form of GFP is expressed under a synthetic RELA-promoter (4x PLAU-promoter); 
in the presence of a cell-permeable compounds (Shield1) GFP is stabilized and accumulates 
inside the cell. This allows for active and controllable degradation of GFP and low background 
levels in reporter gene assays. Stable transfectants were used in all experiments. Green 
fluorescence was examined by fluorescence microscopy or flow cytometry; technical controls 
included addition of excessive Shield-1, which produced strong GFP conditions in all cells 
(serving as a positive control for hGSC cells without TNFα-inducible reporter-gene activity). 
In vivo models 
Animal experiments were carried out in compliance with the German law on animal welfare, 
and all animal protocols were approved by the “Regierung von Oberbayern” in Munich, 
Germany. Mice were housed in standardized cages in the Walter Brendel Centre for 
Experimental Medicine, Ludwig-Maximilians-University (LMU) Munich, received chow ad 
libitum and were kept under a circadian rhythm with 12 h light and dark cycles in 
environmentally enriched conditions (max. 4 mice / cage).  
To evaluate the capacity of the generated mouse gliomas to induce tumors in vivo, adult male 
and female mice (equal ratio; bred at the facility) were randomized, anesthetized and 
immobilized in flat-skull position in a stereotactic head holder. 0,1x 106 cells/1 µl/mouse were 
inoculated using a 30-gauge Hamilton syringe approximately 1,5mm posterior and 1,5 mm 
lateral to the bregma. After operation, the skin was sutured, and mice placed back in their cage 
for recovery. The animals were inspected twice a day until humane end-point (when 
neurological symptoms occur that are firmly associated with end-stage disease). They were then 
anesthetized, perfused with PFA and their brain collected. Brains were placed in 30% sucrose 
for dehydration and cryopreserved in tissueTek O.C.T solution. Tumorigenesis was evaluated 
by hematoxylin-eosin staining, MR imaging and/or immunohistochemical staining.  
For the induction of tumorigenicity in transgenic models concentrated virus particles were 
injected into the SVZ of young (P30) mice at the following stereotactic coordinates (using the 
bregma as a landmark): Antero-posterior +0.6 mm, medio-lateral 1.2 mm, dorso-ventral 1.2 
mm. A volume of 0.5 µl concentrated virus-particles was infused (at a rate of 0.05 µl/ min) 
using an automated pump system.  For in vivo CBD-application (drugs were applied in a fixed 
time-schedule) and Kaplan-Meier read-out immunodeficient mice were inoculated with hGSC 
or transgenic mice were infused with retroviral vectors (VSV-G pseudotyped) for the 
expression of proto-oncogenes. Tumorigenicity was determined by histological inspection of 
random samples from these cohorts of mice. After establishing tumor-growth mice were i.p. 
injected (every other day, for 21 days) with CBD (15mg/kg) or vehicle (5% Tween80, 5% 
ethanol in 0.9% saline). 
MRI screening 
For the MRI screening, mice were anesthetized with inhalation of isoflurane 2% (v/v) in an 
oxygen flow rate of 2 L/min. Imaging was performed on a 7 T small animal MR scanner 
(Agilent Discovery MR901 magnet and gradient system, Bruker AVANCE III HD 
electronics). A 72 mm dual-tuned 1H/13C birdcage resonator was used for radiofrequency 
transmission in combination with a two-channel fixed-housing mouse-brain surface-receiver 
array (Rapid Biomedical, Germany). T2-weighted images were acquired with a fast spin echo 
/ rapid imaging with relaxation enhancement (RARE) sequence, with slice thickness 1 mm, 
field of view 20x20 cm, acquisition matrix 192x192, repetition time 2500 ms, effective echo 
time 40 ms, and fat-suppression enabled.  
Immunofluorescence 
Permeabilized cells were washed 3 times in 1x PBS. The primary antibodies incubated 
overnight at 4°C, washed 3 times with 1 x PBS and incubated in the dark for 2 hours at room 
temperature with a mixture of fluorescently labeled secondary antibody and Hoechst 33342 for 
nuclear counter-staining. Controls included e.g. omission of secondary antibody to exclude 
unspecific immunofluorescence-detection; quantification was performed using ImageJ 
providing data on fold-changes in time-course and pharmacological experiments: Nuclei 
(stained with DAPI) and RelA-immunofluorescence were visualized in separate channels, 
negative controls were used to define a detection-threshold for RelA and corrected total nuclear 
fluorescence (defined as the integrated density of fluorescence-staining of the nuclear region 
after background-subtraction) was obtained for each nucleus.  Thereby we defined a first image-
mask containing information on the size and position of all nuclei. Then we obtained a second 
mask containing results on specific RelA-staining. Both image-masks were overlayed and 





Provider Cat-Nr. RRID  
Rabbit anti NG2 Millipore AB5320 AB_11213678  
Mouse anti- Polysialic- 
Acid- NCAM 60  
Millipore  MAB 5324  AB_11210572  
Goat anti Doublecortin  SantaCruz sc-271390 AB_10610966  
Mouse anti Tuj1 Sigma T8578 AB_1841228  
Mouse anti NeuN  Abcam ab104224 AB_10711040  
Rabbit anti GFAP Abcam ab7260 AB_305808  
Mouse anti-S100ß  Sigma-Aldrich S2532 AB_477499  
Mouse anti-CNpase  Abcam ab6319 AB_2082593  
Rabbit anti Myelin 
Basic Protein 
Abcam ab40390 AB_1141521  
Rabbit anti-Sox 2  Abcam ab97959 AB_2341193  
Goat anti-Sox 2  R&D Systems AF2018 AB_355110  
Rabbit anti-NFκB p65 
Antibody 
BioLegend 622601 AB_315955  
Rabbit anti-Phospho- 
NF-B p65 (Ser311) 
Thermo Fisher PA5-37720 AB_2554400  
Mouse anti-HLA-
A,B,C Alexa Fluor-647 
Biolegend 311414 AB_493135  
Mouse anti-PARP1 
(cleaved Asp214) -
eFluor 450,  























GTX70220 AB_372637  
rabbit anti-NFKB 
p65  
Biolegend 622602 AB_315956  
 
  
Secondary antibodies and conjugated fluorophores  
Antibody  Provider Cat-Nr. RRID 
Biotynilated 
donkey anti mouse 
 Jackson 
Immuno 
Research   
715-065-151 AB_2340785 




Research   
711-545-152 AB_2313584 
Alexa Fluor 594 
donkey anti rabbit 
 Jackson 
Immuno 
Research   
711-585-152 AB_2340621 
Alexa Fluor 594   
donkey anti rat 
 Jackson 
Immuno 
Research   
712-585-150 AB_2340688 
Alexa Fluor 594  
donkey anti mouse 
 Jackson 
Immuno 
Research   
715-585-151 AB_2340855 




Research   
705-545-147 AB_2336933 




Research   
712-605-153 AB_2340694 




Research   
705-605-003 AB_2340436 
Alexa Fluor 488 
conj. Streptavidin 
  Jackson 
Immuno 




 Bio Rad 170-5046 AB_11125757 
HRP conj. anti-
rabbit  
 Bio Rad 170-5047 AB_11125753 
 
Western blotting 
SDS-PAGE was performed to assess nuclear localization and phosphorylation of NFKB. 
Nuclear/cytoplasm separation was performed using an NE-PER kit (#78833, Thermofisher 
Scientific). Protein concentration was determined using a Bradford protein assay kit (#500-
0202, Quick Start Bradford Protein Assay Kit 2, Bio-Rad). Samples (30 μg of protein per lane) 
were denatured in Lämmli buffer (#1610737, Biorad), loaded onto 10% acrylamide gels 
(A3699; Merck) and proteins separated by SDS-PAGE at 150 V for 80 min. Separated proteins 
were transferred to a polyvinylidene fluoride (PVDF) membrane (BioRad) at 400mA for 70 
min. Non-specific antibody sites were blocked with 5% milk powder for 60 min at room 
temperature. Membranes were probed with primary and (after extensive washing) secondary 
antibodies (see tables). For protein size estimation, the precision plus protein WesternC 
standard was used in combination with Streptactin conjugate (1:3000; #1610376 and #1610381, 
Biorad). Blots were developed with Supersignal West Pico Plus Chemoluminescent substrate 
kit (#34578, Thermofisher Scientific) and images were recorded on a Hamamatsu ORCA-ER 
imager using the Wasabi Image software (Hamamatsu Photonics). 
Flow cytometry 
106 cells were exposed to different experimental paradigms, centrifuged, and washed once with 
1xPBS; cells were stained with fluorescently labeled surface antibody in FACS buffer (PBS 
with 0.5% BSA and 2mM EDTA; 1µg antibody/ 106 cells/ 100µl FACS buffer) for 30 minutes 
on ice in the dark; washed twice with FACS buffer, and transferred to FACS tubes for 
acquisition in a LSR Fortessa (Becton Dickinson). For detection of intracellular antigens cells 
were fixed for 20 minutes at RT, permeabilized, washed and incubated with staining solution 
(as above). Cells were always kept on ice, in the dark until flow cytometric acquisition. To 
quantify the relative amount of fluorescence molecules that corresponds to the acquired median 
fluorescence intensity (MFI), rainbow calibration particles (RCP) where acquired the same day 
and using the same laser settings as the samples.  Exported fcs files were analyzed in FCS 
express5 (De Novo Software) for MFI and molecules of equivalent fluorescein (MEFL) using 
a standard curve with pre-defined RCP MEFL concentrations. The normalized median 
fluorescence intensity (nMFI) was also calculated by dividing the MFI by the number of events 
(MFI/number of events). 
For ex vivo imaging of hGSC ROS levels immune-deficient mice bearing patient-derived hGSC 
xenografts were sacrificed and brains collected. The tumor was dissected, tumor biopsy cut into 
10mg pieces, and mashed through a cell strainer. The cell suspension was stained with human 
HLA A, B, C-AlexaFluor647 and 20μM H2DCFDA in 1x PBS for 30 minutes at 37◦C and 
analyzed by flow cytometry as outlined above.  
Reagents for flow cytometry  
Reagent  Provider Cat-Nr. 
CellRox Deep Red reagent  Molecular probes C10422 
Fixable viability dye eFluor-506  eBioscience 65-0866-14 
HCS nucler mask Deep Red 
stain 
 Molecular probes H10294 
H2-DCFDA  Molecular probes D399 
Hoechst 3342  Molecular probes H3570 
Fluorometric Intracellular Ros 
Kit 
 Merck Milllipore MAK-142-IKT 
LYNX Rapid RPE-Cy7 antibody 
conjugation 
 BioRad LNK111PECY7 
LYNX Rapid antibody 
conjugation kit 
 BioRad LNK021RPE 
MitoSox Red  Molecular probes M36008 
MitoLite-blue FX490  AAT Bioquest ABD-22674 
MitoSpy green  BioLegend 424805 
Propidium iodide  Merck Milllipore P4864 
Rainbow calibration particle  BioLegend 422903 
ROSstar550  Li-Cor 926-20000 
ROSstar800CW  Li-Cor 926-80000 
 
Statistical analysis  
Data-distribution was presented by mean-values and standard deviation of the mean; numbers 
of independent experiments or individual animals was indicated in the figures, legends or in the 
manuscript text. Student’s t, one-way/ two-way ANOVA with Tukey post-hoc test or ANOVA 
with Bonferroni correction were used as indicated; in survival experiments, Kaplan–Meier 
curves were used and Log-rank (Mantel-Cox) test was applied to determine statistical 
significance; primary endpoint was development of neurological symptoms clearly indicative 
of hGSC. P values are indicated as *p<0.05, **p<0.005, and ***p<0.0005 in all results. All 
statistical analyses were conducted using Graph Pad Prism 5. 
Table: Software for data analysis 
Software  Provider / citation Application 
Axiovision Rel 4.8  Zeiss Image acquisition 
bcl2Fastq 2.15.04  Illumina Sequencing data 
analysis 
BD coherent connection  BD Biosciences Flow cytometry 
BD FacsDiva  BD Biosciences Flow cytometry 
https://www.cbioportal.org/  Cancer Discov.  2012, 
2(5):401-4. 
Sci Signal. 2013, 
6(269):pl1. 
Data mining 
http://www.chilibot.net/  BMC Bioinformatics. 2004, 
5:147 
Data mining 
CLC Genomics Workbench 
9.5.3 
 Qiagen Sequencing data 
analysis 
CLC Sequence Viewer 8  Qiagen Visualization / design 
of genetic code 
http://designstudio.illumina.com/  Illumina Visualization / design 
of genetic code 
    
FCS Express 5  DeNovo Software Flow cytometry 
FlowJo  FlowJo Flow cytometry 
http://gliovis.bioinfo.cnio.es/  Neuro Oncol. 2017, 
19(1):139-141. 
Data mining 
Graph Pad Prism 5  GraphPad Software Statistics 
https://imagej.net/Fiji  Nature Methods. 2012, 9: 
676–682 
Image processing 
SoftMax Pro  Molecular Devices Microplate reader 
Tecan i-Control  Tecan Microplate reader 
ViiA7™ software 
 





Supplementary Table 3: Biopsies from high-grade astrocytomas
Code Gender Age Diagnosis Primary/ Recurrent
138 female 44 astrocytoma WHO III primary
139 female 50 astroglial tumor cells recurrent 
140 male 54 GBM recurrent
141 male 46 GBM primary
142 male 68 GBM primary
143 male 72 GBM primary
